异动解读 | aTyr Pharma股价盘前暴跌79.77%，肺病新药后期试验未达主要目标

异动解读

Sep 15

周一盘前交易中，生物制药公司aTyr Pharma（ATYR）股价大幅下跌79.77%，投资者对公司核心产品研发失利反应强烈。

根据公司最新公告，aTyr Pharma的实验性药物efzofitimod在针对肺肉瘤病（一种影响肺部和淋巴结的炎症性疾病）患者的后期临床试验中未能达到主要目标。这项为期48周的研究共招募了268名患者，旨在证明与安慰剂相比，efzofitimod能更大程度地减少患者每日类固醇使用量。然而，结果显示，接受较高剂量（5毫克/千克）efzofitimod治疗的患者组，其平均每日类固醇用量降至2.79毫克/千克，而安慰剂组为3.52毫克/千克，两者差异在统计学上并不显著。

尽管试验结果不尽如人意，但aTyr Pharma表示，efzofitimod的安全性与先前的研究结果一致。公司计划与美国食品药品监督管理局（FDA）官员会面，讨论该药物的未来发展方向。目前，已获批准的肺肉瘤病一线治疗方法主要是皮质类固醇激素，如泼尼松。对于无反应或不能耐受类固醇的患者，通常采用甲氨蝶呤和硫唑嘌呤等二线疗法。aTyr Pharma此次研发失利，无疑打击了市场对公司开发新型治疗方案的期待，从而导致股价大幅下挫。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125274879"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125274879\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125274879?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-15 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125274879","market":"sg","top_or_hot":-1,"title":"异动解读 | aTyr Pharma股价盘前暴跌79.77%，肺病新药后期试验未达主要目标","media":"异动解读","content":"<p>周一盘前交易中，生物制药公司aTyr Pharma（ATYR）股价大幅下跌79.77%，投资者对公司核心产品研发失利反应强烈。</p>\n\n<p>根据公司最新公告，aTyr Pharma的实验性药物efzofitimod在针对肺肉瘤病（一种影响肺部和淋巴结的炎症性疾病）患者的后期临床试验中未能达到主要目标。这项为期48周的研究共招募了268名患者，旨在证明与安慰剂相比，efzofitimod能更大程度地减少患者每日类固醇使用量。然而，结果显示，接受较高剂量（5毫克/千克）efzofitimod治疗的患者组，其平均每日类固醇用量降至2.79毫克/千克，而安慰剂组为3.52毫克/千克，两者差异在统计学上并不显著。</p>\n\n<p>尽管试验结果不尽如人意，但aTyr Pharma表示，efzofitimod的安全性与先前的研究结果一致。公司计划与美国食品药品监督管理局（FDA）官员会面，讨论该药物的未来发展方向。目前，已获批准的肺肉瘤病一线治疗方法主要是皮质类固醇激素，如泼尼松。对于无反应或不能耐受类固醇的患者，通常采用甲氨蝶呤和硫唑嘌呤等二线疗法。aTyr Pharma此次研发失利，无疑打击了市场对公司开发新型治疗方案的期待，从而导致股价大幅下挫。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | aTyr Pharma股价盘前暴跌79.77%，肺病新药后期试验未达主要目标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | aTyr Pharma股价盘前暴跌79.77%，肺病新药后期试验未达主要目标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-09-15 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>周一盘前交易中，生物制药公司aTyr Pharma（ATYR）股价大幅下跌79.77%，投资者对公司核心产品研发失利反应强烈。</p>\n\n<p>根据公司最新公告，aTyr Pharma的实验性药物efzofitimod在针对肺肉瘤病（一种影响肺部和淋巴结的炎症性疾病）患者的后期临床试验中未能达到主要目标。这项为期48周的研究共招募了268名患者，旨在证明与安慰剂相比，efzofitimod能更大程度地减少患者每日类固醇使用量。然而，结果显示，接受较高剂量（5毫克/千克）efzofitimod治疗的患者组，其平均每日类固醇用量降至2.79毫克/千克，而安慰剂组为3.52毫克/千克，两者差异在统计学上并不显著。</p>\n\n<p>尽管试验结果不尽如人意，但aTyr Pharma表示，efzofitimod的安全性与先前的研究结果一致。公司计划与美国食品药品监督管理局（FDA）官员会面，讨论该药物的未来发展方向。目前，已获批准的肺肉瘤病一线治疗方法主要是皮质类固醇激素，如泼尼松。对于无反应或不能耐受类固醇的患者，通常采用甲氨蝶呤和硫唑嘌呤等二线疗法。aTyr Pharma此次研发失利，无疑打击了市场对公司开发新型治疗方案的期待，从而导致股价大幅下挫。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATYR","symbol_name":"ATYR PHARMA INC","start_time":0,"source_url":"","article_id":"1125274879","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125274879","pubTimestamp":1757939424,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"周一盘前交易中，生物制药公司aTyr Pharma股价大幅下跌79.77%，投资者对公司核心产品研发失利反应强烈。根据公司最新公告，aTyr Pharma的实验性药物efzofitimod在针对肺肉瘤病患者的后期临床试验中未能达到主要目标。尽管试验结果不尽如人意，但aTyr Pharma表示，efzofitimod的安全性与先前的研究结果一致。目前，已获批准的肺肉瘤病一线治疗方法主要是皮质类固醇激素，如泼尼松。aTyr Pharma此次研发失利，无疑打击了市场对公司开发新型治疗方案的期待，从而导致股价大幅下挫。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ATYR":"ATYR PHARMA INC"},"translate_title":"Interpretation of changes | aTyr Pharma's stock price plummeted 79.77% before the market, and the late-stage trial of new lung disease drugs failed to reach the main goal","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATYR":1},"content_text":"周一盘前交易中，生物制药公司aTyr Pharma（ATYR）股价大幅下跌79.77%，投资者对公司核心产品研发失利反应强烈。\n根据公司最新公告，aTyr Pharma的实验性药物efzofitimod在针对肺肉瘤病（一种影响肺部和淋巴结的炎症性疾病）患者的后期临床试验中未能达到主要目标。这项为期48周的研究共招募了268名患者，旨在证明与安慰剂相比，efzofitimod能更大程度地减少患者每日类固醇使用量。然而，结果显示，接受较高剂量（5毫克/千克）efzofitimod治疗的患者组，其平均每日类固醇用量降至2.79毫克/千克，而安慰剂组为3.52毫克/千克，两者差异在统计学上并不显著。\n尽管试验结果不尽如人意，但aTyr Pharma表示，efzofitimod的安全性与先前的研究结果一致。公司计划与美国食品药品监督管理局（FDA）官员会面，讨论该药物的未来发展方向。目前，已获批准的肺肉瘤病一线治疗方法主要是皮质类固醇激素，如泼尼松。对于无反应或不能耐受类固醇的患者，通常采用甲氨蝶呤和硫唑嘌呤等二线疗法。aTyr Pharma此次研发失利，无疑打击了市场对公司开发新型治疗方案的期待，从而导致股价大幅下挫。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}